It's kinda weird to me that despite the company saying repeatedly that they met their primary endpoints, and that the results are clinically meaningful, and that they are confident they have pathways to partnership deals, that posters here are questioning the results and in effect saying the company is misrepresenting the effectiveness of the drug. It's not really a matter of opinion: the company has a legal obligation to report the results accurately, and in this case they say the trial met its endpoints.
Ann: Paradigms Supplementary Phase 2B Data, page-5
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $83.98M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 24.0¢ | $202.2K | 814.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 181098 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 118621 | 5 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |